Evaluation of Breast Disorders - Gynecology and Obstetrics - Merck

Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) —dedicated to using leading-edge science to save and improve lives around the world. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge.

PPT - Screening for Breast cancer PowerPoint Presentation, free download - ID:8816564

The Clinical Impact of the Women's Health Initiative (WHI): Entering a New Era in Managing Postmenopausal Health Issues

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer - Modern Pathology

Key Decision Points in Neoadjuvant and Adjuvant Treatment Selection for Early-Stage HER2-Negative Breast Cancer

Frontiers Comparison of intraoperative radiotherapy as a boost vs. simultaneously integrated boosts after breast-conserving therapy for breast cancer

Frontiers Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

Cancers, Free Full-Text

PDF) Challenging ChatGPT 3.5 in Senology—An Assessment of Concordance with Breast Cancer Tumor Board Decision Making

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer - Modern Pathology

Cancers, Free Full-Text

PDF) First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Frontiers Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer